Vishesh Agarwal, MD
Psychiatry · Wilmington, DENPI 1609163971
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,598 of the $45,574 with a category attached, or 78.1%. E.r. Squibb & Sons, L.L.C. accounts for 91.6% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $41,712, more than ten times the $22 reported in 2020. Among psychiatry clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 68 payments — averaging $670.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$42K
- Boehringer Ingelheim$3K
- Neurocrine Biosciences, Inc.$123
- Medtronic$119
- Johnson & Johnson$61
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$26
- plus $22 from 1 others
Across 61 payments — averaging $352.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$22K
What the payments were for
- Consulting fees$5,56612%
- Speaking & faculty fees$35,59878%
- Travel & lodging$2,5086%
- Food & beverage$1,9024%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 58 | $41,748 |
| Boehringer Ingelheim | 3 | $3,475 |
| Neurocrine Biosciences, Inc. | 1 | $123 |
| Medtronic | 1 | $119 |
| Johnson & Johnson | 3 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$37,425
- INGREZZA$123
- SYNCHROMEDII$119
How this compares
$45,574 in reported general payments places this provider in the 95th percentile of 114 psychiatry providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 59 | $173,529 |
| Abilify MaintenaAripiprazole | 19 | $52,773 |
| Risperdal ConstaRisperidone Microspheres | 23 | $45,981 |
| ClozarilClozapine | 14 | $19,193 |
| Clozapine | 40 | $4,354 |
| Divalproex Sodium | 59 | $1,007 |
| Gabapentin | 64 | $739 |
| Fluoxetine Hcl | 33 | $668 |
| Quetiapine Fumarate | 27 | $618 |
| Haloperidol | 25 | $587 |
| Divalproex Sodium ErDivalproex Sodium | 27 | $581 |
| Perphenazine | 13 | $534 |
| Benztropine Mesylate | 62 | $414 |
| Buspirone Hcl | 18 | $323 |
| Olanzapine | 21 | $314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $61 | $219,51082 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 114 psychiatry providers in Delaware.
Other psychiatry in Wilmington
- Ranganathan RamWilmington$202K
- Manisha WadhwaWilmington$89K
- Kathlyn RowenWilmington$5K
- Sandeep GuptaWilmington$4K
- Nana BerikashviliWilmington$3K
- Karl McIntoshWilmington$2K
- Fawzia HasanWilmington$2K
- Jose CapiroWilmington$1K
- Imran TrimziWilmington$1K
- Chandrakala KathiravanWilmington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.